PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20814160-3	2010	Hydroxylation activities of mfCYP3A4 and mfCYP3A5 toward coumarin, paclitaxel, diclofenac, flurbiprofen, and S-mephenytoin were below detectable levels, as was also true for CYP3A4 and CYP3A5.	Mephenytoin	109-122	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-36	
12900870-2	2003	Mephenytoin (MEPH), dextromethorphan, diclofenac, caffeine, and methadone (MET) were successfully applied as test substrates for CYP2C19, CYP2D6*1, CYP2C9*1, CYP1A2, and CYP3A4, respectively.	Mephenytoin	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176	
15499174-1	2004	Metabolic capacities for debrisoquin, sparteine, mephenytoin, nifedipine, and midazolam, which are substrates of polymorphic CYP2D6, CYP2C19, and CYP3A, have been reported to exhibit, in many cases, remarkable interindividual and ethnic differences.	Mephenytoin	49-60	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	146-151	
10647906-4	1999	Methylenedioxyphenyl compounds which possess a bulky structure such as 1,4-benzothiazine showed substantial inhibition of S-warfarin 7-hydroxylation catalysed by CYP2C9, S-mephenytoin 4"-hydroxylation by CYP2C19, bufuralol 1"-hydroxylation by CYP2D6, and testosterone 6beta-hydroxylation by CYP3A4.	Mephenytoin	170-183	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	291-297	
7581498-5	1995	We have used mephenytoin, debrisoquine and dapsone as selective probes for the phenotypic measures of activity of CYP2C19, CYP2D6, and CYP3A4, respectively.	Mephenytoin	13-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-141	
8820421-4	1996	Ketoconazole and troleandomycin, both selective inhibitors for cytochrome P450 3A4 (CYP3A4), markedly inhibited the formation of all oxidative metabolites of MK-639; whereas other inhibitors (furafylline, sulfaphenazole, quinidine, S-mephenytoin, and diethyldithiocarbamate) had little effect on MK-639 metabolism.	Mephenytoin	232-245	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	63-82	
8820421-4	1996	Ketoconazole and troleandomycin, both selective inhibitors for cytochrome P450 3A4 (CYP3A4), markedly inhibited the formation of all oxidative metabolites of MK-639; whereas other inhibitors (furafylline, sulfaphenazole, quinidine, S-mephenytoin, and diethyldithiocarbamate) had little effect on MK-639 metabolism.	Mephenytoin	232-245	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	84-90	
9732386-5	1998	CYP2B6 levels were found to significantly (P < .0001) correlate with S-mephenytoin N-demethylation to nirvanol (r2 = 0.89), 7-hydroxy-4-trifluoromethylcoumarin formation (r2 = 0.81) and several markers of CYP3A levels and activity.	Mephenytoin	72-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	208-213	
9357389-10	1997	We concluded that CYP3A4 catalyzes the sulfoxidation of omeprazole and that this is the predominant metabolic pathway of omeprazole in poor metabolizers of S-mephenytoin.	Mephenytoin	156-169	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	18-24	
8548776-5	1996	The formation of hydroxydocetaxel was strongly reduced by CYP3A inhibitors such as ketoconazole, midazolam, erythromycin, testosterone, orphenadrine, and troleandomycin, whereas quinidine (CYP2D6), hexobarbital, tolbutamide, and mephenytoin (CYP2C) had no or little effect.	Mephenytoin	229-240	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-63